Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressure

Roche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion Swiss francs (about $18.8 billion), and the company expects mid‑single‑digit sales growth for 2026.

Executives highlighted a breast‑cancer candidate, giredestrant, and a portfolio of four obesity medicines that are in mid‑ or late‑stage development. They projected that the combined peak sales of these products could reach more than $9 billion a year.

Roche also warned that eight of its cancer and immune‑disease drugs face biosimilar competition, which could reduce sales by roughly 41% between 2025 and 2030. While the pipeline offers growth potential, some Wall Street analysts remain cautious about the outlook.